Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label retinal gene therapy study of AAV2-REP1 for choroideremia
2015-001383-18Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Mar 2016
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timrepigene emparvovec in choroideremia, sponsored by University of Oxford. Primary endpoint: Change from baseline in best corrected visual acuity in the treated eye. Status: unknown.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on 2015-001383-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001383-18.